NRXP NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.

$0.73
As of 09/29/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/04/2017
Outstanding shares:  67,641,314
Average volume:  262,752
Market cap:   $47,646,542
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BL5F9Z4
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.31
PS ratio:   0.00
Return on equity:   -1,143.40%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy